Navigation Links
Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
Date:8/21/2008

penses:

Cost of

products

sold 27,211,681 (154,726) (253,879)(2,012,734) 24,790,342

Research

and

development 17,200,762 (92,630) (849,678) (10,250) 16,248,204

Sales and

marketing 14,747,333 (71,474) (262,148)(2,382,915) 12,030,796

General

and

admini-

strative 12,827,771 (4,898)(1,627,173)(2,482,929) 8,712,771

Loss on

sale of

endovascular

assets 1,212,478 - - (1,212,478) -

Total

operating

costs

and

expenses 73,200,025 (323,728)(2,992,878)(8,101,306) 61,782,113

Income from

operations 6,590,872 323,728 2,992,878 8,101,306 18,008,784

Interest and

other income,

net 15,088 - - - 15,088

Pre-tax

income 6,605,960 323,728 2,992,878 8,101,306 18,023,872

Income tax

expense 1,816,179 108,606 1,004,066 2,717,867 5,646,717

Net income $4,789,781 $215,122 $1,988,812 $5,383,439 $12,377,155

Basic

earnings

per share $0.40 $0.02 $0.17 $0.45 $1.04

Diluted

earnings

per share $0.38 $0.02 $0.16 $0.43 $0.99

Weighted

average

common

shares

outstand-

ing 11,891,469 11,891,469 11,891,469 11,891,469 11,891,469

Diluted

weighted

average

common

shares

outstanding 12,471,298 12,471,298 12,471,298 12,471,298 12,471,298


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
3. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
4. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
7. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arpida Reports Interim Results for Six Months to 30 June 2008
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... the thinnest-possible semiconductor, a new class of nanoscale ... , The University of Washington researchers have demonstrated ... be connected in an atomically seamless fashion known ... basis for next-generation flexible and transparent computing, better ... "Heterojunctions are fundamental elements of electronic and photonic ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Mers CoV virus ... Replikin structures back to 2012.  This conservation and sharing ... of a Synthetic Mers CoV Blocker-Vaccine™ candidate, as it did ... Shrimp vaccine, both of which have been found to ...
(Date:8/26/2014)... been added to the growing case for graphene ... big thing in the high-tech world by the ... collaboration of researchers led by a scientist with ... National Laboratory (Berkeley Lab) has reported the first ... MX2 materials. The recorded charge transfer time clocked ...
(Date:8/26/2014)...  ViveBio, LLC a leading provider of products ... announced today that it has signed a distribution ... Knoxville, Tennessee to distribute ... United States . ViveST is the first ... biological specimen transport systems.  The technology enables easy, ...
Breaking Biology Technology:Scientists craft atomically seamless, thinnest-possible semiconductor junctions 2Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2
... Distributor in Greece, to Purchase an Aggregate ... of Over $200,000 of Resurgex(R) in 2008, ... wholly owned subsidiary of Millennium,Biotechnologies Group, Inc. (OTC Bulletin Board: ... order for the international,distribution of the Resurgex(R) line in Greece. ...
... CAMBRIDGE, Mass., April 1, 2008 Abt ... Abt Bio-Pharma Solutions, Inc., a,wholly owned subsidiary of ... custom strategic, research and communication solutions for the,pharmaceutical, ... approach that blends decades of experience with wide,ranging ...
... MONTREAL, April 1 /PRNewswire-FirstCall/ - AEterna,Zentaris Inc. ... global biopharmaceutical company,focused on endocrine therapy and ... leading Canadian specialty pharmaceutical company, announced today,that, ... transactions under their,previously announced purchase and sale ...
Cached Biology Technology:Millennium Announces $200,000 Purchase Order From Greek Distributor 2Millennium Announces $200,000 Purchase Order From Greek Distributor 3Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 2AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights 3
(Date:8/27/2014)... to Europe based upon a proxy for impact have ... ,big data, approach to scientific research. , The researchers ... ranked the top 100 pathogens affecting humans and the ... they believe, will help governments across the continent plan ... including as a result of climate change, and for ...
(Date:8/27/2014)... . , Charcot-Marie-Tooth ... affecting the peripheral nervous system. Researchers from the Department ... Medicine and University Medical Centre Gttingen have discovered that ... with the disease. These cells enwrap the nerve fibres ... the rapid transfer of electrical impulses. If Schwann cells ...
(Date:8/27/2014)... York, NY (June, 2014) Outstanding basic research, ... and a dedication to patient care have earned ... Columbia University Medical Center (CUMC) and NewYork-Presbyterian Hospital ... from the National Cancer Institute (NCI). The grant ... two NCI-designated Comprehensive Cancer Centers in New York ...
Breaking Biology News(10 mins):Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... has named its awardee for this year,s Alan ... Brown University. Dunn,s work involves genome analyses ... He investigates the origins of biological complexity ... research holds clues about how complex multicellular organisms, ...
... This release is available in French . ... without exposing the healthy surrounding tissue to the medication,s toxic ... medical reality, thanks to the work of Professor Sylvain Martel, ... Known for being the world,s first researcher to have guided ...
... most controversial aspects in the sustainable management of golf courses. ... the practices relating to reclaimed water at one of the ... on the course receive 83% more water than they need. ... be justified from any perspective", Mara del Pino Palacios Daz, ...
Cached Biology News:Casey Dunn to receive NSF Waterman Award 2Casey Dunn to receive NSF Waterman Award 3World first -- Localized delivery of an anti-cancer drug by remote-controlled microcarriers 2Golf courses that reuse water irrigate too much 2Golf courses that reuse water irrigate too much 3
Yersinia pestis...
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
Biology Products: